Bank of America’s Turnstone Biologics TSBX Stock Holding History

Bank of America’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-150	Closed	-$54	–	8691
2025 Q2	$54	Sell	150 -891,381	-100%	-$312K	﹤0.01%	8086
2025 Q1	$366K	Buy	891,531 +5	+0%	+$2	﹤0.01%	5826
2024 Q4	$442K	Sell	891,526 -20,215	-2%	-$9.98K	﹤0.01%	5640
2024 Q3	$508K	Buy	911,741 +960	+0.1%	+$1.47K	﹤0.01%	5475
2024 Q2	$2.39M	Buy	910,781 +11,408	+1%	+$32.6K	﹤0.01%	4310
2024 Q1	$2.36M	Sell	899,373 -14,685	-2%	-$42K	﹤0.01%	4312
2023 Q4	$2.33M	Buy	914,058 +905,543	+10,635%	+$2.36M	﹤0.01%	4254
2023 Q3	$33.5K	Buy	+8,515	New	+$75.9K	﹤0.01%	6594

Bank of America's TSBX Position: Q3 2025 in Review

Bank of America sold out of Turnstone Biologics (TSBX) in Q3 2025, closing a stake of 150 shares — an estimated $54 sold.

Bank of America first reported a position in TSBX in Q3 2023 and held it in 8 quarters. The position peaked at $2.39M in Q2 2024. 1 fund tracked by Wall St. Rank holds TSBX as of Q3 2025.

Bank of America reported no remaining Turnstone Biologics position as of Q3 2025 after selling out during the quarter.
Bank of America sold 150 Turnstone Biologics shares in Q3 2025, an estimated $54.
Bank of America first reported a position in Turnstone Biologics in Q3 2023 and held it in 8 quarters.
Bank of America's Turnstone Biologics position peaked at $2.39M in Q2 2024.
1 fund tracked by Wall St. Rank held Turnstone Biologics as of Q3 2025.

Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.